News

The trial established that the drug had significantly improved the progression-free survival (PFS) in ovarian cancer patients with germline BRCA-mutations (gBRCA) whose disease had relapsed, and had also

The commercial license builds on an existing research and clinical licensing agreement for select disease areas. Under the terms of the license, Crispr Therapeutics and Casebia will obtain

Pfizer expects to launch Zavicefta in additional markets outside the U.S. throughout 2017 and 2018. Zavicefta was developed in response to the urgent medical need for new antibiotics

Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, has been approved to treat adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after

The companies will focus on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain. Under the terms of the

No new safety signals or unexpected safety findings were seen in this long-term safety study. The profile of observed adverse events (AEs) was similar to that reported for

Kisqali, which is a selective cyclin-dependent kinase inhibitor, has been approved as initial endocrine-based therapy to treat postmenopausal women with hormone receptor positive and human epidermal growth factor

Synairgen is collaboraing with Australian firm Pharmaxis on the program which will target scar tissue that inhibits breathing in sufferers of idiopathic pulmonary fibrosis (IPF), a lethal lung condition. If

Orphan drug designation is granted by the FDA to investigational compounds intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect